High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$16.7M
$16,655,740
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
CRSP
S
CRISPR Therapeutics AG
KASINGER JAMES R.
• Officer • General Counsel and Secretary
Sell to Cover
2026-03-23
$148,854
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
Officer • General Counsel and Secretary
Sell to Cover
|
2026-03-23 | $148,854 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CEO
Sell to Cover
|
2026-03-23 | $468,736 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
Sell to CoverΔOwn -19.2%
|
2026-03-23 | $173,460 | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
KASINGER JAMES R.
• Officer • General Counsel and Secretary
Sell to Cover
2026-03-16
$166,497
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
Officer • General Counsel and Secretary
Sell to Cover
|
2026-03-16 | $166,497 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CEO
Sell to Cover
|
2026-03-16 | $499,443 | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
Patel Naimish
• Officer • Chief Medical Officer
Sell to CoverΔOwn -19.3%
2026-03-16
$152,019
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
Officer • Chief Medical Officer
Sell to CoverΔOwn -19.3%
|
2026-03-16 | $152,019 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
Sell to CoverΔOwn -22.6%
|
2026-03-16 | $476,278x2 | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
KASINGER JAMES R.
• Officer • General Counsel and Secretary
Sell to Cover
2026-03-11
$147,840
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
Officer • General Counsel and Secretary
Sell to Cover
|
2026-03-11 | $147,840 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CEO
Sell to Cover
|
2026-03-11 | $517,334 | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
KASINGER JAMES R.
• Officer • General Counsel and Secretary
Sell to Cover
2026-02-19
$111,049
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
Officer • General Counsel and Secretary
Sell to Cover
|
2026-02-19 | $111,049 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CEO
Sell to Cover
|
2026-02-19 | $366,325 | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
Kulkarni Samarth
• CEO
10b5-1 SellΔOwn -30.9%
2026-01-22
$3,613,800Large
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
CEO
10b5-1 SellΔOwn -30.9%
|
2026-01-22 | $3,613,800Large | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -83.8%
|
2026-01-22 | $2,104,965Large | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CEO
10b5-1 Sell
|
2026-01-20 | $1,552,498Largex2 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -28.5%
|
2026-01-06 | $1,786,636Largex3 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -12.9%
|
2025-12-22 | $559,549x3 | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
Kulkarni Samarth
• CEO
Sell to CoverΔOwn -16.7%
2025-10-17
$3,456,279Large
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
CEO
Sell to CoverΔOwn -16.7%
|
2025-10-17 | $3,456,279Large | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
KASINGER JAMES R.
• Officer • General Counsel and Secretary
Sell to Cover
2025-10-14
$71,662
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
Officer • General Counsel and Secretary
Sell to Cover
|
2025-10-14 | $71,662 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CEO
Sell to Cover
|
2025-10-14 | $282,517 | S | Form 4 |